Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has prepared and tested new bispecific antibody-drug conjugates (ADCs) consisting of a bispecific antibody or antigen-binding fragments targeting B7 homolog 3 (B7-H3; CD276) and delta-like protein 3 (DLL3) linked to cytotoxic drug; they are described as potentially useful for the treatment of cancer.